Health Sciences Authority Singapore

What Health Sciences Authority Singapore does

Health Sciences Authority (HSA) is a Singapore government statutory board established on 1 April 2001 under the Ministry of Health, functioning as the national regulator for health products, the principal provider of forensic science services, and the operator of the national blood service. HSA regulates medicines, medical devices, cosmetics, traditional medicines, health supplements, and tobacco through dedicated legislation and e-service platforms including PRISM, SHARE, CTGTP E-Services, and VaSER. Its Forensic Medicine and Science Division delivers toxicology, DNA profiling, document examination, and illicit drug analysis to support criminal investigations, anchored by a Tissue Typing Lab dating to 1988 and a national forensic DNA database that provides structural data advantages. The Blood Services Group operates five regional blood banks serving the public hospital system.

The agency's business model is hybrid: government appropriations underwrite the bulk of operations while fee-based regulatory charges (product registration, licensing, laboratory testing) recover a portion of costs from regulated manufacturers, importers, and clinical trial sponsors. HSA holds WHO Maturity Level 4 designation, the highest tier for a national regulatory authority, which positions Singapore as a recognised reference jurisdiction for clinical trial data and accelerates market access for novel therapies such as the IASO Bio CAR-T cell therapy currently under review. Recent strategic activity, including the HPRG Innovation Office, the HealthPoints/yuu Rewards blood donation partnership with Singapore Red Cross, and the VaSER vape enforcement platform, signals active expansion of mandate and digital product surface.

HSA's CEO, Adjunct Professor (Dr) Raymond Chua, leads a workforce of 501-1,000 across multiple Singapore office locations, including the Biopolis and Outram campuses. Operating revenues are not publicly disclosed as the entity functions primarily on appropriations rather than commercial sales. Strategic priorities visible in 2026 include medtech gateway positioning, advanced biologics regulation, vape enforcement, and donor recruitment through consumer loyalty incentives.

Name

Health Sciences Authority Singapore

Legal name

Health Sciences Authority

Website

https://hsa.gov.sg

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Health Sciences Authority (HSA) is a Singapore statutory board under the Ministry of Health that regulates health products, provides forensic science services, and operates five national blood banks for manufacturers, law enforcement, hospitals, and the public.

Ownership category

akta.pro rank

Product category

Health Product Regulation

NAICS

Blood and Organ Banks (621991), Testing Laboratories and Services (541380)

SIC

Services-Health Services (8000), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Regulatory Compliance, Licensing & Enforcement (Public Health) (HLAJAMAE)

akta.pro secondary industries

Healthcare Licensing, Accreditation & Credentialing Boards (HLAJACAC), Health Regulation, Licensing & Compliance (Public Health) (BPAIAJAN), Data Governance, Standards & Interoperability (ICD, HL7/FHIR, LOINC, SNOMED) (HLAJAJAM)

Keywords

• Health product regulation
• Medical device regulation
• Pharmaceutical regulation
• Blood banking services
• Forensic science services

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Pricing tiers

Distribution channels8 records

Marketing channels7 records

Core offering

Health Sciences Authority (HSA) is Singapore's statutory board that regulates health products (therapeutic products, medical devices, cell/tissue/gene therapy products, cosmetics, Chinese proprietary medicines, traditional medicines, health supplements, and tobacco/vaporisers), manages the national blood supply through a network of bloodbanks and mobile donation drives, and delivers applied sciences services including forensic medicine, analytical toxicology, DNA profiling, illicit drugs testing, tissue typing, and chemical metrology. It operates electronic service portals such as PRISM and SHARE that allow commercial users to submit regulatory applications and view product information.

Product overview

The Health Sciences Authority (HSA) operates a platform of regulatory e-services for health product regulation in Singapore. The core offering consists of multiple e-service portals including PRISM (for therapeutic products, tobacco, cosmetics, clinical trials), SHARE (for medical devices), CTGTP E-Services (for cell, tissue and gene therapy products), and Infosearch (health products database). These are complemented by regulatory services for medical devices, therapeutic products, cosmetics, traditional medicines, health supplements, and tobacco. HSA also operates the national blood donation program through five Bloodbanks and mobile drives, and provides lab services through its Applied Sciences division including forensic medicine, toxicology, and tissue typing. The HPRG Innovation Office supports medtech and biomedical innovation in Singapore.

Differentiator

Problem solved

Functional benefit

Brands

• HSA: Official acronym for Health Sciences Authority used across communications and branding

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Singapore Red Cross (SRC)coreStrategic or Co-development Partner · 1 April 2001The Singapore Red Cross was appointed as the national blood donor recruiter in April 2001. HSA and SRC work in partnership to collect blood from donors on a voluntary, non-remunerated basis under the National Blood Programme. SRC focuses on recruitment and retention of blood donors, promotion and education on blood donation importance, and organisation of mobile blood donation drives.

Recent moves6 records

Expansion highlights5 records

Regional players

• NHS Blood and Transplant (NHSBT): UK's national blood service operator — comparable in mission and operational scope to HSA's Blood Services Group (collection, testing, processing, distribution), but serves a different geography.

Broad incumbents

• National Medical Products Administration (NMPA China): China's national health products regulator with overlapping scope but a much larger domestic market and broader product category coverage.
• Vitalant: One of the largest US nonprofit blood services organizations — comparable mission and operational model to HSA's Blood Services Group at significantly larger scale.
• US Food and Drug Administration (FDA): The largest national health products regulator globally; broader scope covering food, drugs, devices, cosmetics, and tobacco — the dominant reference regulator HSA benchmarks against.

Others

• Eurofins Scientific: Global leader in forensic, pharmaceutical, and analytical testing services — comparable to HSA's Applied Sciences Division for forensic toxicology, document examination, and chemical metrology work.

Direct peers

• Health Canada: Canadian national health regulator covering therapeutic products, medical devices, and biologics with similar stringent authority and licensing model.
• Singapore Red Cross: Appointed national blood donor recruiter in 2001, working in close partnership with HSA under the National Blood Programme; directly collaborates on blood collection, donor recruitment, and mobile drives.
• Therapeutic Goods Administration (TGA Australia): Australia's national regulator for therapeutic goods, medical devices, and blood products with comparable scope, maturity tier, and registration/licensing functions. Closest comparable in size and remit.
• Pharmaceuticals and Medical Devices Agency (PMDA Japan): Japan's pharmaceutical and medical device regulator with similar stringent regulatory authority and Asia-Pacific gateway positioning.
• Medicines and Healthcare products Regulatory Agency (MHRA UK): UK's national health products regulator with comparable regulatory, licensing, and adverse event reporting functions; another WHO-listed stringent regulator comparable in scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/HSAsg
• YouTubeyoutube.com/user/HSAsingapore
• LinkedInlinkedin.com/company/health-sciences-authority
• Instagraminstagram.com/hsa.singapore

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Sciences Authority Singapore